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JP-45 is a novel integral protein constituent of the
skeletal muscle sarcoplasmic reticulum junctional face
membrane. We identified its primary structure from a
cDNA clone isolated from a mouse skeletal muscle cDNA
library. Mouse skeletal muscle JP-45 displays over 86
and 50% identity with two hypothetical NCBI data base
protein sequences from mouse tongue and human muscle,
respectively. JP-45 is predicted to have a cytoplasmic do-
main, a single transmembrane segment followed by an in-
tralumenal domain enriched in positively charged amino
acids. Northern and Western blot analyses reveal that the
protein is mainly expressed in skeletal muscle. The mRNA
encoding JP-45 appears in 17-day-old mouse embryos; ex-
pression of the protein peaks during the second month of
postnatal development and then decreases 3-fold during
aging. Double immunofluorescence of adult skeletal muscle
fibers demonstrates that JP-45 co-localizes with the sarco-
plasmic reticulum calcium release channel. Co-immuno-
precipitation experiments with a monoclonal antibody
against JP-45 show that JP-45 interacts with the 1.1 sub-
unit voltage-gated calcium channel and calsequestrin.
These results are consistent with the localization of JP-45
in the junctional sarcoplasmic reticulum and with its in-
volvement in the molecular mechanism underlying skeletal
muscle excitation-contraction coupling.
The sarcoplasmic reticulum is an intracellular membrane
compartment that controls the intracellular calcium concentra-
tion and, therefore, plays an important role in excitation-con-
traction (E-C)1 coupling (1–3). The anatomical site of E-C cou-
pling is the triad, an intracellular synapse formed by the
association of two membrane compartments: the transverse
tubules, which are an invagination of the plasmalemma, and
the terminal cisternae (2–4). The portion of terminal cisternae
facing the transverse tubules is called the junctional face mem-
brane. Two major protein constituents of the triad membranes
have been identified and shown to play a crucial role in E-C
coupling: the skeletal muscle voltage-gated calcium channel
dihydropyridine receptors (DHPRs) localized in T-tubule mem-
brane and the ryanodine receptors (RyRs) localized in the sar-
coplasmic reticulum junctional face membrane (5–9). In skele-
tal muscle the DHPRs respond to transverse tubule
depolarization by sensing the voltage variation and induce
calcium release from the skeletal muscle sarcoplasmic reticu-
lum (SR) via direct activation of the RyR (8, 9).
Besides RyRs, the sarcoplasmic reticulum junctional face
membrane contains a number of proteins, including triadin,
calsequestrin, and junctin (10) as well as other known and
unknown proteins (11–16). Because of their localization, pro-
teins present within this membrane are likely to be involved in
E-C coupling, and a defect in their function could potentially
lead to alterations of the calcium release process and/or intra-
cellular homeostasis leading to neuromuscular diseases
(16–21).
We recently identified JP-45, an integral membrane polypep-
tide of 45 kDa of skeletal muscle junctional face membrane
(22). In the present investigation, we extended our studies and
carried out the molecular characterization of JP-45. Our re-
sults show that this polypeptide is mainly expressed in skeletal
muscle and that its level of expression is down-regulated dur-
ing aging. In addition, we show that it interacts with two key
proteins involved in skeletal muscle E-C coupling, namely the
1.1 subunit of the DHPR and calsequestrin.
EXPERIMENTAL PROCEDURES
Materials
Keyhole-limpet hemocyanin (KLH) conjugation kit, MPLTDM ad-
juvant, CHAPS, and protein G-Sepharose were from Sigma; glutathi-
one-Sepharose 4B, pGex plasmid, nitrocellulose membranes, and
[32P]dCTP were from Amersham Biosciences. Goat anti- 1.1 subunit of
the skeletal muscle DHPR polyclonal antibodies were from Santa Cruz
Biotechnology Inc. RNA isolation kit was from Biotecx Laboratories
(Houston, TX). Anti-calsequestrin antibodies were raised in guinea pigs
and previously characterized (23). Fluorescein isothiocyanate- and
TRITC-conjugated secondary antibodies were from DAKO. Sheep anti-
RyR antibodies were from Upstate Biotechnology (Lake Placid, NY).
Peroxidase-conjugated protein G and protein A were from Bio-Rad.
Peroxidase-conjugated secondary antibodies, antiprotease mixture, the
chemiluminescence kit, restriction enzymes, random primed DNA la-
beling kit, DNA-digoxigenin labeling kit, and anti-digoxigenin peroxi-
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dase-conjugated antibodies were from Roche Applied Science and New
England Biolabs. Mouse skeletal muscle UNI-ZAP XR cDNA library
and the cDNA synthesis kit were from Stratagene. Mouse multiple-
tissue Northern blot, RNA master blot, and the pEGFP plasmids were
from Clontech. All other chemicals were of reagent grade.
Methods
cDNA Cloning—We isolated and purified total RNA from Balb/c mice
skeletal muscles using an RNA isolation kit from Biotecx Laboratories
following the instructions provided by the manufacturer. Total RNA
was converted into cDNA using a cDNA synthesis kit from Roche
Applied Science using oligo(dT)15 primers, following the instructions
provided by the manufacturer. To amplify the cDNA specific for JP-45,
we first searched the NCBI data base for sequences matching the
polypeptide sequences we obtained from rabbit skeletal muscle JP-45
(22). The available sequences matched a hypothetical mouse tongue
protein (Mus musculus; NCBI accession number AK009578). Based on
the primary sequence of this hypothetical protein, we designed a set of
primers to amplify the portion of JP-45 encompassing almost all of the
peptide sequences we had obtained by tryptic and CNBr digestion of the
native protein. The primers used to amplify the cDNA corresponding to
JP-45 cDNA were 5-AGAATTCCCGCCCCCAAGACGCCAAGC-3 and
5-AGAATTCACGGCCTTTATTTGCTGGTGC-3 for forward and re-
verse reactions, respectively. The EcoRI restriction enzyme sequence
was added to facilitate subsequent subcloning. 100 ng of mouse skeletal
cDNA were amplified in a PerkinElmer Life Sciences GeneAmp 2400
PCR system under the following conditions: 5 min at 95 °C, followed by
35 cycles of 40 s annealing at 63 °C, 45 s extension at 72 °C and 30 s
denaturation at 92 °C, and a final elongation step of 4 min at 72 °C. The
nature and identity of the amplified cDNA was verified by direct se-
quencing (Microsynth AG, Balgach, Switzerland). The PCR-amplified
cDNA fragment was labeled and used to screen a mouse skeletal muscle
UNI-ZAP XR cDNA library as previously described (24).
Northern Blot Analysis—Northern blot filters containing 2 g of
poly(A) RNA from eight different mouse tissues and a dot blot con-
taining poly(A) RNA from mouse embryos were hybridized with a
32P-labeled cDNA probe obtained from the full-length clone, 193C-1, as
previously described (24).
Monoclonal Antibody Production—Mouse monoclonal antibodies
were generated against a synthetic peptide designed on a sequence
derived from a sequence of rabbit skeletal muscle JP-45. The peptide
was conjugated to the keyhole-limpet hemocyanin carrier and used to
immunize Balb/c mice. Splenocytes from the immunized mice were
fused with tissue culture-grown myeloma cells (AGX8) and hybridomas
selected in hypoxanthine/aminopterin/thymidine (HAT) medium. Hy-
bridoma cells were identified and tested for the presence of anti-JP-45
antibodies by Western blot analysis on rabbit terminal cisternae
(22, 25).
Expression of JP-45 in Mammalian Cells and Tissues—The entire
coding sequence of JP-45 was cloned in-frame into the pEGFP-C1 vector
by amplifying the cDNA by PCR using the following forward and re-
verse primers, 5-AGAATTCTATGACTACCAGAGGCCTGG-3 and 5-
AGGTACCACACAGGATCAGTC-3, respectively, under the same con-
ditions as described above. Expression of the recombinant protein was
monitored by fluorescence microscopy on COS-7 cells (Lipofectin) trans-
fected either with pEGFP alone or pEGFP-JP-45, using an Axiophot
Zeiss fluorescent microscope equipped with NeoFLUAR objective (63
oil, N.A.  1.40) as previously described (24).
Chemical skinning of soleus rat muscles was performed as previously
described (26). Single fibers were then isolated under a dissecting
microscope, transferred into a Petri dish chamber containing 0.5 ml of
a relaxing solution (170 mM K-propionate, 2.5 mM Mg-propionate, 5 mM
K2EGTA, 10 mM imidazole, pH 7.0, 5 mM K2Na2ATP) and inserted, in a
slightly stretched position, between two clamps. The procedure for
immunofluorescence staining was initiated by incubating fibers for 1 h
in the relaxing solution containing 1% Triton X-100 (RS-T) and 10%
goat non-immune serum. All following steps, both washings and incu-
bation with primary or secondary antibodies, were carried out by using
the RS-T. Fibers were first incubated for 90 min with the anti-JP
45-kDa antibody (2 g/ml), washed three times, then incubated for 40
min with the goat anti-mouse IgG TRITC-conjugated secondary anti-
body (1:100) in the presence of 1% rat non-immune serum. After wash-
ing, fibers were then incubated with a sheep polyclonal antibody spe-
cific for the rabbit skeletal muscle ryanodine receptor (diluted 1:200).
After 90 min, fibers were washed three times and incubated 40 min
with goat anti-sheep IgG fluorescein isothiocyanate-conjugated second-
ary antibody (1:100). After the final wash, fibers were removed from
clamps, mounted in an Elvanol solution on glass slides, and observed
with a Leica DMRB fluorescent microscope equipped with a CCD cam-
era. Captured images were analyzed with image processing software
(Casti Imaging, Padova, Italy).
TSA201 cells with the pEGFP and pEGFP-JP-45 constructs were
transfected; 48 h post-transfection, cells were harvested and crude
microsomal membranes prepared by differential centrifugation steps
(3,000  gmax, 15,000  gmax, 150,000  gmax). Integral microsomal
membrane components were separated from their soluble counterpart
by high salt wash (0.6 M KCl) and extraction with 100 Na2CO3 at alkali
pH as previously described (11). Microsomes were also prepared from
the brain, tongue, heart, liver, spleen, kidney, and skeletal muscles of
2-month-old Balb/c mice as well as from the skeletal muscles of 4-day-,
2-month-, 10-month-, and 14.5-month-old Balb/c mice, as described
previously (22, 24). For the latter preparations, which were used to
examine the changes that occur in JP-45 during development, four
different preparations from at least four different mice were used.
Electrophoresis and Immunological Staining—SDS-PAGE and indi-
rect immunostaining were carried out as previously described. Protein
concentration was determined as described by Bradford (31), using
bovine serum albumin as standard (22, 24).
Co-immunoprecipitation Assay—Vesicles derived from the light (R1)
and heavy (R4) skeletal muscle membrane fractions and from triads
were prepared as previously described (25). Proteins were solubilized
(at a final concentration of 1 mg/ml) in a buffer composed of 200 mM
NaCl, 50 mM Tris-HCl, pH 8.5, 1 mM dithiothreitol, 1% CHAPS, and
anti-proteases for 30 min at room temperature. Soluble proteins were
obtained by centrifugation at 150,000  g for 30 min at 4 °C and then
were diluted 10 times with a buffer containing anti-proteases mixture,
200 mM NaCl, 50 mM Tris-HCl, pH 8.5, and finally incubated with 1 g
of anti-JP-45 monoclonal antibodies for 1 h. Protein G-Sepharose pre-
viously equilibrated with 10 mM Tris-HCl, 150 mM NaCl (pH 8.0),
0.001% Tween (TBST) was added to precipitate the immunocomplex.
The immunoprecipitated proteins were separated by electrophoresis in
a 10% polyacrylamide gel and then transferred onto nitrocellulose
membranes. The proteins pulled down with JP-45 were detected by
immunoblot analysis using a panel of antibodies specific for proteins
found in triad membranes.
Data Analysis—For group comparison the one-way analysis of vari-
ance test was used.
RESULTS AND DISCUSSION
cDNA Cloning, Sequence Analysis, and Expression of Recom-
binant JP-45 Protein—To obtain the cDNA encoding JP-45, we
matched the amino acid sequence information obtained from
the peptides generated by proteolytic treatment of rabbit skel-
etal muscle JP-45 (22) with sequence information available
from data bases. Our data matched a hypothetical sequence
from mouse (Mus musculus; NCBI accession number
AK009578) tongue. Based on the latter nucleotide sequence, we
designed a set of primers and amplified a 710-bp cDNA frag-
ment (corresponding to nucleotides 590–1319 of the full-length
cDNA encoding JP-45). The nucleotide sequence of the PCR
fragment matched that of sequence AK009578. The PCR frag-
ment was then 32P-labeled and used to screen under high
stringency conditions (three washes at 65 °C, 0.1% SDS, 0.2 
SSCP) a commercially available mouse skeletal muscle cDNA
library. Of 1  106 plaques that were screened, a total of four
positive clones were pulled out, plaque-purified, and sequenced
(Fig. 1, upper panel, 193C, 193C-1, 193C-3, and 193C-4). Two
overlapping clones (193C-1, of 1160 bp, and 193C-3, of 1158 bp)
contain an identical open reading frame of 996 bp correspond-
ing to a 332-amino acid-long polypeptide. Both clones 193C-1
and 193C-3 possess 66 nucleotides in the 5-untranslated re-
gion upstream from the first initiation codon. A single poly-
adenylation signal, AAATAA, is observed 18 nucleotides up-
stream from the poly(A) tail (not shown).
Northern blot analysis of tissues from eight different adult
mice revealed a strong hybridizing transcript of 1.16 kb only
in skeletal muscle; the size of the transcript matches the size of
clone 193C-1 (Fig. 2, upper panel). In addition, the transcript
encoding JP-45 first appears in 17-day-old embryo mice. Mul-
tiple sequence alignment shows that the sequence of the mouse
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FIG. 1. Predicted primary sequence of mouse skeletal muscle JP-45 and comparison of its amino acid sequence to that of mouse
tongue, human muscle, and rabbit skeletal muscle. Top, restriction map of the full-length cDNA clone (193C-1) encoding JP-45 and of three
other partial clones (193C-3, 193C, and 193C-4) also isolated from the mouse skeletal muscle library. The dark shaded rectangles represent the
open reading frame; the small white box represents the poly(A) tail. Bottom, multiple sequence alignment was carried out using the ClustalW
computer program available from the Swiss node of the European Molecular Biology network. Black boxes indicate identical residues; gray boxes
indicate conserved residues. Underlined sequences match the peptide sequences obtained from proteolytic treatment of JP-45.
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skeletal muscle cDNA clone encodes a protein that displays 86
and 50% identity with hypothetical proteins from mouse
tongue and human muscle (Fig. 1, lower panel). The NH2-
terminal sequence of mouse skeletal muscle JP-45 is similar to
its human counterpart but diverges from that of mouse tongue.
The mouse skeletal muscle JP-45 and the hypothetical tongue
protein are identical from Val at position 54 until the end of the
protein. The peptide sequence obtained from proteolytic treat-
ment of rabbit skeletal muscle JP-45 that was used to generate
the anti-JP-45 mAb is localized at the COOH-terminal part of
the proteins and displays 71 and 50% identity with the corre-
sponding mouse and human sequences, respectively.
The deduced primary sequence of mouse skeletal muscle
JP-45 predicts a protein of 332 amino acids with a molecular
mass of 36 kDa. Transmembrane prediction analysis (TMpred,
www.ch.EMBnet.org) suggests the possibility of one trans-
membrane domain, between residues 126–148, which is 100
and 91% identical to the hypothetical mouse tongue and human
muscle sequences, respectively. We confirmed that JP-45 is an
integral membrane protein by cellular and biochemical ap-
proaches. When COS-7 cells were transfected with the pEGFP-
JP-45 construct, the green fluorescence was excluded from the
nuclei and showed a pattern of fluorescence compatible with its
distribution within intracellular membranes (Fig. 3A). On the
other hand, when cells were transfected with the empty pEGFP
vector, the fluorescence was evenly distributed throughout the
cytoplasm and nuclei (Fig. 3B). These results are consistent
with localization of the recombinant EGFP-JP-45 fusion pro-
tein in the sarco(endo)plasmic reticulum membrane. The con-
clusion is also supported by Western blot analysis of KCl-
washed, sodium carbonate-treated membrane fraction isolated
by differential centrifugation from TSA201 cells transfected
with pEGFP-JP-45. A band having a molecular mass of about
70 kDa (27 kDa corresponding to the mass of GFP, plus 45 kDa
corresponding to the apparent mass of JP-45) was immuno-
decorated with anti-GFP (Fig. 3C, lanes 1 and 2) and anti-
JP-45 antibodies (Fig. 3C, lanes 3 and 4) and is clearly present
in the membranes after Na2CO3 extraction (Fig. 3C, lanes 2
and 4) and absent from the soluble fraction (Fig. 3C, lanes 1
and 3). This result is consistent with the conclusion that the
punctuated fluorescent pattern of living COS-7 is not because
of aggregates of denatured recombinant protein within ER
membranes. TSA201 cells transfected with the empty pEGFP
vector display an immunoreactive band of 27 kDa only in the
soluble fraction (Fig. 3D, lane 1).
To localize JP-45 in native muscle fibers, we performed dou-
ble immunofluorescence experiments on adult rat muscle fibers
using our anti-JP-45 monoclonal antibodies and commercially
available anti-RyR receptor antibodies. Staining with either
antibody shows a typical triadic striation pattern (Fig. 3, right
panels, JP45 and RyR). The merged image supports the view
that JP-45 and ryanodine receptor co-localize in triad
membranes.
Mouse skeletal muscle JP-45 contains 112 charged amino
acid residues of a total of 332; the lumenal domain alone
contains 76 (of 112) charged residues, 47 of which are basic and
30 acidic, giving the polypeptide a predicted pI of 9.77. The
higher apparent molecular mass of the JP-45 observed in the
Laemmli gel system could be because of the basic nature of the
protein, as already described for triadin, another basic SR
protein. The protein contains eight putative protein kinase As,
three protein kinase Cs, and five CaMKII phosphorylation
sites.
Tissue Distribution and Developmental Expression of JP-45—
To investigate the tissue distribution at the protein level we used
the monoclonal antibody raised against a synthetic peptide derived
from the rabbit skeletal muscle JP-45 sequence (Fig. 1B, RabbitSk-
Muscpep). It should be pointed out that this mAb immunodecorated
a glutathione S-transferase fusion protein encompassing the
COOH-terminal domain of the mouse skeletal muscle JP-45 (not
shown), indicating that its epitope is shared by the rabbit and
mouse proteins. The presence of the JP-45 protein product in the
microsomal fractions from different mouse tissues was verified by
FIG. 2. Tissue and embryological expression of JP-45. Top, 2 g
of poly(A) RNA per lane from eight different mouse tissues were
hybridized to a 32P-labeled cDNA probe encompassing nucleotides 19–
1047 of mouse skeletal muscle JP-45. Lane 1, heart; lane 2, brain; lane
3, spleen; lane 4, lung; lane 5, liver; lane 6, skeletal muscle; lane 7,
kidney; and lane 8, testes. Center, the blot was hybridized with -actin
cDNA probe as control. Bottom, 1 g of poly(A) RNA from 7-, 11-, 15-,
and 17-day-old mouse embryos was hybridized to a 32P-labeled cDNA
probe encompassing nucleotides 19–1047 of mouse skeletal muscle
JP-45.
FIG. 3. Cellular distribution of JP-45. A and B, cells were exam-
ined for GFP fluorescence with a Zeiss Axiovert microscope using a63
NeoFLUOR objective (1.4 N.A., excitation 480 nm; magnification
1000). C and D, microsomes from TSA201 cells transfected with the
pEGFP-JP-45 and pEGFP plasmids were washed with high salt and
100 mM Na2CO3. Soluble proteins and proteins loosely associated with
the membranes (lanes 1 and 3) were separated from integral membrane
proteins (lanes 2 and 4) by differential centrifugation. 20 g of protein
were loaded per lane, separated on a 10% SDS-PAGE, blotted onto
nitrocellulose, and probed with anti-GFP antibodies (panels C and D,
lanes 1 and 2) or anti-JP-45 antibodies (panel C, lanes 3 and 4). Right
panels, double immunofluorescence staining of chemically skinned sin-
gle fibers from rat soleus muscle with the monoclonal anti-JP-45 anti-
body (JP45), a polyclonal anti-RyR antibody (RYR). The merged image
(merge) shows the overlap of the staining of the two antibodies. Scale
bar  10 m.
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Western blot analysis. An immunoreactive band is present in total
mouse microsomal membranes isolated from skeletal muscle and
tongue (Fig. 4A, lanes 8 and 13) but absent from microsomal mem-
branes of kidney, spleen, liver, heart, and brain (Fig. 4A, lanes 9–12
and 14, respectively).
We next examined whether the expression of JP-45 changes
during development by comparing its content in microsomal
membranes from skeletal muscles obtained from mice of differ-
ent age groups (0.2, 2, 10, and 14.5 months). Four separate SR
preparations from at least four different animals of each age
group were made and their content of JP-45 assessed. A clear
increase in the total content of JP-45 was shown during the
early phase of postnatal development, and the amount of pro-
tein peaks at 2 months (Fig. 4B) and thereafter in 14.5-
month-old mice decreases 3.2-fold (analysis of variance p
0.0036) (Fig. 4C). The average mouse life span is 2 years;
thus, it appears that JP-45 is down-regulated during aging of
mouse skeletal muscle (27, 28).
Protein-Protein Interactions of JP-45 with Skeletal Muscle
Sarcotubular Membrane Proteins—The junctional face mem-
brane of sarcoplasmic reticulum contains proteins that play a
crucial role in the mechanism of E-C coupling. The selective
localization of JP-45 in the junctional face membrane suggests
that this protein may also be involved in the mechanism un-
derlying E-C coupling by interacting with other junctional face
membrane protein constituents. To test this hypothesis, we
carried out co-immunoprecipitation experiments with the anti-
JP-45 mAb. The specificity of the anti-JP-45 mAb was assayed
against vesicles from light R1, R2, and heavy R4 muscle mem-
brane fractions (25, 29, 30). A single immunoreactive band
migrating as a polypeptide of 45 kDa is present in vesicles
derived from light SR but is clearly enriched in the heavy R4
membrane fraction (Fig. 5A). To determine whether JP-45
forms a complex with other proteins present in the sarcoplas-
mic reticulum, we performed co-immunoprecipitation experi-
ments. Vesicles from light R1 and heavy R4 muscle membrane
fractions were solubilized with CHAPS, and the proteins con-
tained in the clarified supernatant were incubated with anti-
JP-45 antibodies followed by incubation with protein G-Sepha-
rose beads. The co-immunoprecipitated proteins were analyzed
by Western blotting using antibodies directed against protein
constituents of the triad membranes. Neither triadin nor the
RyR could be co-immunoprecipitated by the JP-45 antibodies
(results not shown). In the light R1 sarcoplasmic reticulum
fraction, anti-1.1 subunit of the voltage-gated calcium channel
antibodies stained a single polypeptide of 200 kDa (Fig. 5B,
lane 1). When the proteins present in the co-immunoprecipi-
tated complex were probed with the anti-1.1 subunit of the
voltage-gated calcium channel antibodies, an immunoreactive
band with an electrophoretic mobility identical to that present
in the light R1 fraction was obtained (Fig. 5B, lane 3). In control
experiments in which the light R1 sarcoplasmic reticulum frac-
tion was incubated with the Sepharose beads in the absence of
anti-JP-45 mAb (Fig. 5B, lane 4) no immunoreactivity was
obtained, confirming the specificity of the interaction (Fig. 5B,
lane 4). In another control, we incubated the immunoprecipi-
tating anti-JP-45 antibodies with the protein G-Sepharose
beads in the absence of sarcoplasmic reticulum fraction; under
these conditions no immunodecorated band was observed (Fig.
5B, lane 2).
A similar set of experiments was performed to verify whether
calsequestrin was part of the immunoprecipitated complex.
The specificity of the anti-calsequestrin antibodies is shown in
Fig. 5C, lane 1: a polypeptide of 60 kDa is recognized by the
antibodies in the heavy sarcoplasmic reticulum R4 fraction.
When the proteins present in the co-immunoprecipitated com-
plex were probed with the anti-calsequestrin antibodies, an
immunoreactive band of60 kDa was present (Fig. 5C, lane 3).
FIG. 4. Western blot analysis show-
ing tissue distribution and develop-
mental expression of JP-45 protein.
A, gel Coomassie Brilliant Blue staining
(lanes 1–7) or JP-45 immunostaining
(lanes 8–14) of 10 g of microsomes from
different tissues obtained from Balb/c
mice. Lanes 1 and 8, skeletal muscle;
lanes 2 and 9, brain; lanes 3 and 10, heart;
lanes 4 and 11, liver; lanes 5 and 12,
spleen; lanes 6 and 13, kidney; lanes 7 and
14, tongue. B, total microsomes obtained
from Balb/c mouse muscles of the indi-
cated age groups were subjected to SDS-
PAGE and stained with Coomassie Bril-
liant Blue (a) or with anti-JP-45 mAb (b).
Ten micrograms of protein were loaded
per lane. C, densitometric scanning of the
intensity of the JP-45 immunopositive
band from different muscle preparations.
The intensity of the JP-45 immunoposi-
tive band was compared for different mice
of different age groups using the analysis
of variance test (p  0.0036).
Novel Junctional SR Protein (JP-45) Interacts with the DHPR 39991
Control experiments in which no sarcoplasmic reticulum-de-
rived fraction or no immunoprecipitating anti-JP-45 antibodies
were added (Fig. 5C, lanes 2 and 4, respectively) demonstrate
the lack of immunoreactive bands, indicating the specificity of
the interaction.
The specificity of the co-immunoprecipitation reaction was
verified using a different muscle membrane preparation en-
riched in triads (7) as well as by preincubating the precipitating
anti-JP-45 antibodies with their immunogenic peptide. The
anti-JP-45 mAb co-immunoprecipitated the 1.1 subunit of the
voltage-gated calcium channel from CHAPS-solubilized triad
membranes (Fig. 5D) and calsequestrin from R1 CHAPS-solu-
bilized vesicles. At least three concentrations of precipitating
anti-JP-45 antibodies were used (0.5, 0.8, and 1 g protein) and
under our experimental conditions 1 g yielded the best re-
sults. To further verify that the immunoprecipitation was not
because of nonspecific effects, we carried out the co-immuno-
precipitation experiment in the presence of increasing concen-
trations of the competing soluble immunogenic peptide (,
1.3-mg peptide; , 0.9-mg peptide; , no peptide). Our results
show that by blocking the interaction of the antibody with its
antigen, we progressively inhibit precipitation of the
immunocomplex.
In conclusion, the results reported here provide unequivocal
biochemical evidence that the novel JP-45 protein co-localizes
with RyR and interacts with the 1.1 subunit of the voltage-
gated calcium channel DHPR and the sarcoplasmic reticulum
calcium-binding protein calsequestrin, suggesting an impor-
tant role of this protein in the basic mechanisms underlying
E-C coupling in normal and aged skeletal muscle.
REFERENCES
1. Fleischer, S., and Inui, M. (1989) Annu. Rev. Biophys. Biophys. Chem. 18,
333–364
2. Rios, E., and Pizarro, G. (1991) Physiol. Rev. 71, 849–908
3. Franzini-Armstrong, C., and Jorgensen, A. O. (1994) Annu. Rev. Physiol. 56,
509–534
4. Ikemoto, N., Yano, M., El-Hayek, R., Antoniu, B., and Morii, M. (1994) Bio-
chemistry 33, 10961–10968
5. Sutko, J. L., and Airey, J. A. (1996) Physiol. Rev. 76, 1027–1071
6. Nakai, J., Dirksen, R. T., Nguyen, H. T., Pessah, I. N., Beam, K. G., and Allen,
P. D. (1996) Nature 380, 72–75
7. Marty, I., Robert, M., Villaz, M., De Jongh, K., Lai, Y., Catterall, W. A., and
Ronjat, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2270–2274
8. Nakai, J., Sekiguchi, N., Rando, T. A., Allen, P. D., and Beam, K. G. (1998)
J. Biol. Chem. 273, 13403–13406
9. Lamb, G. D., and Stephenson, D. G. (1990) J. Physiol. (Lond) 423, 519–542
10. Zhang, L., Kelley, J., Schmeisser, G., Kobayashi, Y. M., and Jones, L. R. (1997)
J. Biol. Chem. 272, 23389–23397
11. Costello, B., Chadwick, C., Saito, A., Chu, A., Maurer, A., and Fleischer, S.
(1986) J. Cell Biol. 103, 741–753
12. MacLennan, D. H., and Wong, P. T. (1971) Proc. Natl. Acad. Sci. U. S. A. 68,
1231–1235
13. Hamilton, S. L., Serysheva, I., and Strasburg, G. M. (2000). News Physiol Sci.
15, 281–284
14. Meissner, G. (1994) Annu. Rev. Physiol. 56, 485–508
15. Franzini-Armstrong, C., and Protasi, F. (1997) Physiol. Rev. 77, 699–729
16. Marks, A. R., Marx, S. O., and Reiken, S. (2002) Trends Cardiovasc. Med. 12,
166–170
17. Timerman, A. P., Ogunbumni, E., Freund, E., Wiederrecht, G., Marks, A. R.,
and Fleischer, S. (1993) J. Biol. Chem. 268, 22992–22999
18. Nishi, M., Komazaki, S., Kurebayashi, N., Ogawa, Y., Noda, T., Iino, M., and
Takeshima, H. (1999) J. Cell Biol. 147, 1473–1480
19. Pan, Z., Yang, D., Nagaraj, R. Y., Nosek, T. A., Nishi, M., Takeshima, H.,
Cheng, H., and Ma, J. (2002) Nat. Cell Biol. 4, 379–383
20. Jurkat-Rott, K., McCarthy, T., and Lehmann-Horn, F. (2000) Muscle Nerve 23,
4–17
21. McCarthy, T. V., Quane, K. A., and Lynch, P. J. (2000) Hum. Mutat. 15,
410–417
22. Zorzato, F., Anderson, A. A., Ohlendieck, K., Froemming, G., Guerrini, R., and
Treves, S. (2000) Biochem. J. 351, 537–543
23. Treves, S., Vilsen, B., Chiozzi, P., Andersen, J. P., and Zorzato, F. (1992)
Biochem. J. 283, 767–772
24. Treves, S., Feriotto, G., Moccagatta, L., Gambari, R., and Zorzato, F. (2000)
J. Biol. Chem. 275, 39555–39568
25. Saito, A., Seiler, S., Chu, A., and Fleisher, S. (1984) J. Cell Biol. 99, 875–885
26. Biral, D., Senter, L., and Salviati, G. (1996) J. Muscle Res. Cell Motil. 17,
523–532
27. Kempermann, G., Gast, D., and Gage, H. (2002) Ann. Neurol. 52, 135–143
28. Silver, M. (1995) Mouse Genetic. Oxford University Press, New York
29. Sacchetto, R., Damiani, E., and Margreth, A. (2001) J. Muscle Res. Cell. Motil.
22, 545–559
30. Damiani, E., Tobaldin, T., Bortoloso E., and Margreth, A. (1997) Cell Calcium
22, 129–150
31. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254
FIG. 5. Immunoprecipitation of solubilized light and heavy SR
fractions. A, immunoreactivity of the anti-JP-45 monoclonal antibod-
ies. Twenty micrograms of rabbit skeletal muscle R1, R2, and R4
sarcoplasmic reticulum-derived vesicles were separated on a 10% SDS
PAGE and probed with 0.5 g/ml anti-JP-45 mAb. The immune reac-
tion was visualized with anti-mouse peroxidase-conjugated antibodies
followed by chemiluminescence. B and C, thirty micrograms of rabbit
skeletal muscle R1 or R4 sarcoplasmic reticulum-derived vesicles were
separated on a 10% SDS PAGE and probed with 0.5 g/ml anti-1.1
subunit of the voltage-gated calcium channel (panel B, lane 1) and
anti-calsequestrin (panel C, lane 1) antibodies. CHAPS-solubilized ves-
icles were immunoprecipitated with 1 g of anti-JP-45 mAb as de-
scribed under “Experimental Procedures.” The pulled-down proteins
were separated in a 10% SDS PAGE, blotted onto nitrocellulose, and
probed with anti-1.1 subunit of the voltage-gated calcium channel or
anti-calsequestrin antibodies. Abbeads, control; no SR-derived pro-
teins were present. Abbeadsfract, proteins bound to the beads and
forming an immune complex. Beadsfract, control, no antibody pres-
ent. The immune reaction was visualized with protein G or protein A
peroxidase conjugates, respectively, followed by chemiluminescence.
Conditions were as described under “Experimental Procedures.” D,
conditions as described in panels B and C except that co-immunopre-
cipitation was carried out in the absence ( peptide) or presence (,
1.3-mg peptide; , 0.9-mg peptide) of increasing concentrations of im-
munogenic peptide (Abbeadsfraction proteins bound and forming an
immune complex). Void, proteins not bound to the Abbeads. The blots
were probed with anti-1.1. subunit of the voltage-gated calcium chan-
nel and anti-calsequestrin antibodies as described for panels B and C.
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